Cabaletta Bio (CABA) Q2 Loss Widens 30%
Cabaletta Bio (NASDAQ:CABA), a biotechnology firm developing cell therapies for autoimmune diseases, released its financial results for the quarter on August 7, 2025. The headline news was a deepened net loss per share of $(0.73) (GAAP), as the company invested heavily in both research and administrative activities. Cash and investments increased to $194.7 million due to a substantial equity raise. The quarter showed ongoing operational progress, highlighted by rapid clinical trial enrollment, new regulatory alignment with the United States Food and Drug Administration (FDA), and a clear focus on pushing multiple pipeline programs toward late-stage trials. There was no product revenue, and no formal guidance was provided beyond an updated operating cash runway projection.
Source: Analyst estimates for the quarter provided by FactSet.
Cabaletta Bio develops chimeric antigen receptor T cell (CAR-T) therapies. These therapies use a patient’s own re-engineered immune cells to target disease-causing cells. Currently, its lead product candidate is rese-cel, a CAR-T therapy aimed at treating serious autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, and myasthenia gravis. The company does not yet have an approved product on the market, so funding comes from equity and partnerships.
Source Fool.com
